HealthRX.com · Printable lab tracker
Liver tracker for tirzepatide in MASLD: enzymes, scans, weight and gallbladder symptoms
Record the liver tests and scans this page lists at baseline, 12 weeks and 24 weeks and every 6 months after that, beside your weight and dose. It keeps the label's gallbladder warning signs and the trial results that set realistic expectations.
Baseline
How MASLD was diagnosedultrasound, MRI-PDFF, FibroScan, biopsy
Fibrosis stage or liver stiffness, if known
Diabetes and latest HbA1c
Starting weight
Alcohol in a typical week
Results over time
| Test | Baseline | Week 12 | Week 24 | Month 12 | Notes |
|---|---|---|---|---|---|
| ALT | |||||
| AST | |||||
| GGT | |||||
| Platelet count | |||||
| Liver fat or stiffness scan | |||||
| Weight | |||||
| HbA1c | |||||
| Tirzepatide dose (mg) |
What the trials and the label say
- In SYNERGY-NASH, MASH resolved without worse fibrosis in 44% to 62% of people on tirzepatide, against 10% on placebo, after 52 weeks.[1]
- In SURPASS-3 MRI, liver fat fell 8.09 points on tirzepatide 10 mg or 15 mg, against 3.38 points on insulin degludec.[2]
- The label recommends no Mounjaro dose change for hepatic impairment.[3]
- In placebo-controlled adult trials, gallbladder problems (gallstones, biliary colic or gallbladder removal) were reported by 0.6% on Mounjaro and 0% on placebo.[3]
Do not wait for the next visit
- Pain in your upper stomach, fever, yellowing of your skin or eyes, or clay-colored stools (possible gallbladder problems): tell your healthcare provider right away.[3]
- Severe stomach pain that will not go away, with or without vomiting: stop Mounjaro and call your healthcare provider right away.[3]
Questions for the visit
- Which test will show whether my liver is improving?
- Do I need a fibrosis assessment before starting?
- What weight change are we aiming for, and by when?
- Is a gallbladder ultrasound worth doing before I start?
- Is resmetirom or another liver-specific treatment an option for me?
Sources for the facts on this sheet
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 2024. PMID 38856224. https://pubmed.ncbi.nlm.nih.gov/38856224/
- Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022. PMID 35468325. https://pubmed.ncbi.nlm.nih.gov/35468325/
- Eli Lilly and Company, via DailyMed. Mounjaro (tirzepatide) injection, for subcutaneous use: prescribing information and Medication Guide. Effective 2026-08-27. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.